Bayer AGXSWX:BAYN 39 Return-on-Tangible-Asset is 19.00% as of Mar. 2026, which is 625% above its 10-year median of 2.62. GuruFocus rates XSWX:BAYN with a GF Score™ of 39/100 and a GF Value™ of CHF24.61 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Bayer AG ranks worse than 70.95% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Bayer AG's annualizedNet Income for the quarter that ended in Mar. 2026 was CHF10,059 Mil. Bayer AG's average total tangible assets for the quarter that ended in Mar. 2026 was CHF52,954 Mil. Therefore, Bayer AG's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 19.00%.
The historical rank and industry rank for Bayer AG's Return-on-Tangible-Asset or its related term are showing as below:
XSWX:BAYN'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -19.6 Med: 2.62 Max: 14.52
Current: -3.76
During the past 13 years, Bayer AG's highest Return-on-Tangible-Asset was 14.52%. The lowest was -19.60%. And the median was 2.62%.
XSWX:BAYN's Return-on-Tangible-Asset is ranked worse than 70.95% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 3.15
vs XSWX:BAYN: -3.76
Bayer AG (XSWX:BAYN) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Bayer AG Return-on-Tangible-Asset Related Terms
Bayer AG Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Bayer AG's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:BAYN vs LLY, JNJ, ABBV: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - General subindustry, Bayer AG's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bayer AG Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bayer AG's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Bayer AG's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 19.00% mean?
Bayer AG (XSWX:BAYN) has a Return-on-Tangible-Asset of 19.00% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Bayer AG and its competitors. This is 625% above median its historical median of 2.62. According to the industry distribution chart, Bayer AG ranks #713 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 70.9%.
Is Bayer AG's Return-on-Tangible-Asset too high?
Bayer AG's current Return-on-Tangible-Asset of 19.00% is 625% above median its 10-year median of 2.62. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.15. Bayer AG's value of 19.00% is 503.2% above this industry median. Based on the distribution chart, Bayer AG ranks #713 out of 1005 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Bayer AG has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bayer AG's Return-on-Tangible-Asset compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Bayer AG ranks #713 out of 1005 companies for Return-on-Tangible-Asset. This places Bayer AG in the lower half of its industry. The industry median Return-on-Tangible-Asset is 3.15. Bayer AG's value of 19.00% is 503.2% above this benchmark. While the company's 10-year median is 2.62 vs. the industry median of 3.15, Bayer AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.15, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bayer AG's current Return-on-Tangible-Asset of 19.00% is 503.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Bayer AG and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bayer AG's current Return-on-Tangible-Asset is 19.00%, which is 625% above median its own 10-year median of 2.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayer AG stock overvalued right now?
Based on GuruFocus' analysis, Bayer AG (XSWX:BAYN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF24.61, compared to a current price of CHF43.29 — trading 75.9% above its estimated fair value. The current Return-on-Tangible-Asset is 19.00%, which is 625% above median its 10-year median of 2.62 and 503.2% above the Drug Manufacturers industry median of 3.15. Bayer AG's overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Bayer AG (XSWX:BAYN), the current Return-on-Tangible-Asset is 19.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bayer AG (XSWX:BAYN) Overvalued in 2026?
Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued.
The current stock price of CHF43.29 is trading 75.9% above its estimated GF Value™ of CHF24.61.
GuruFocus considers Bayer AG to be Significantly Overvalued.
Key valuation signals for XSWX:BAYN:
Return-on-Tangible-Asset: 19.00% (625% above median its 10-year median of 2.62)
GF Value™: CHF24.61 vs. price of CHF43.29 (75.9% above fair value)
Industry Position: 503.2% above the Drug Manufacturers median (#713 of 1005)
No single metric tells the full story. See the XSWX:BAYN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
39GF Score
Get the complete analysis for XSWX:BAYN
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BAYN has been successfully added to your 
